Diagnostic Value of Fractional Exhaled Nitric Oxide (FeNO)

  • Kazuto MatsunagaEmail author
Part of the Respiratory Disease Series: Diagnostic Tools and Disease Managements book series (RDSDTDM)


Asthma is a heterogeneous disease, usually characterized by chronic inflammation of the airways. Fractional nitric oxide (NO) concentration in exhaled air (FeNO) is recognized as a noninvasive biomarker of eosinophilic inflammation in the lower respiratory tract. Presence of airway inflammation in addition to respiratory symptoms that are suggestive of asthma supports a diagnosis of asthma. This chapter provides recent topics pertaining to asthma including the mechanism of production of NO in the airway, methods of and interpretations in measuring FeNO, and the role of exhaled NO measurement in making diagnosis of asthma and differentiating asthma from chronic obstructive pulmonary disease (COPD).


Asthma Airway inflammation COPD Exhaled nitric oxide Type 2 



Asthma-COPD overlap


Chronic obstructive pulmonary disease


Endothelial nitric oxide synthase


Fractional nitric oxide concentration in exhaled air


Forced expiratory volume in one second


Forced vital capacity


Inducible nitric oxide synthase


Nitric oxide


Neuronal nitric oxide synthase


Reactive oxygen species


  1. 1.
    American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med. 2005;171:912–30.CrossRefGoogle Scholar
  2. 2.
    Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR, American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–15.CrossRefGoogle Scholar
  3. 3.
    Ichinose M, Sugiura H, Nagase H, Yamaguchi M, Inoue H, Sagara H, Tamaoki J, Tohda Y, Munakata M, Yamauchi K, Ohta K, Japanese Society of Allergy. Japanese guidelines for adult asthma. Allergol Int. 2017;66:163–89.CrossRefGoogle Scholar
  4. 4.
    Ichinose M, Takahashi T, Sugiura H, Endoh N, Miura M, Mashito Y, Shirato K. Baseline airway hyperresponsiveness and its reversible component: role of airway inflammation and airway caliber. Eur Respir J. 2000;15:248–53.CrossRefGoogle Scholar
  5. 5.
    Matsunaga K, Kawabata H, Hirano T, Sugiura H, Minakata Y, Ichnose M. Difference in time-course of improvement in asthma control measures between budesonide and budesonide/formoterol. Pulm Pharmacol Ther. 2013;26:189–94.CrossRefGoogle Scholar
  6. 6.
    Matsunaga K, Hirano T, Akamatsu K, Minakata Y. Predictors for identifying the efficacy of systemic steroids on sustained exhaled nitric oxide elevation in severe asthma. Allergol Int. 2013;62:359–65.CrossRefGoogle Scholar
  7. 7.
    Alving K, Malinovschi A. Basic aspects of exhaled nitric oxide. Eur Respir Mon. 2010;49:1–31.Google Scholar
  8. 8.
    Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med. 2000;162:701–6.CrossRefGoogle Scholar
  9. 9.
    Matsunaga K, Hirano T, Kawayama T, Tsuburai T, Nagase H, Aizawa H, Akiyama K, Ohta K, Ichinose M. Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. Allergol Int. 2010;59:363–7.CrossRefGoogle Scholar
  10. 10.
    Matsunaga K, Hirano T, Akamatsu K, Koarai A, Sugiura H, Minakata Y, Ichinose M. Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects. Allergol Int. 2011;60:331–7.CrossRefGoogle Scholar
  11. 11.
    Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO workshop report 2017.Google Scholar
  12. 12.
    Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:418–24.CrossRefGoogle Scholar
  13. 13.
    McDonald VM, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68:691–4.CrossRefGoogle Scholar
  14. 14.
    Konstantelou E, Papaioannou AI, Loukides S, Bartziokas K, Papaporfyriou A, Papatheodorou G, Bakakos P, Papiris S, Koulouris N, Kostikas K. Serum periostin in patients hospitalized for COPD exacerbations. Cytokine. 2017;93:51–6.CrossRefGoogle Scholar
  15. 15.
    Tamada T, Sugiura H, Takahashi T, Matsunaga K, Kimura K, Katsumata U, Takekoshi D, Kikuchi T, Ohta K, Ichinose M. Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations. Int J Chron Obstruct Pulmon Dis. 2015;10:2169–76.CrossRefGoogle Scholar
  16. 16.
    Akamatsu K, Matsunaga K, Sugiura H, Koarai A, Hirano T, Minakata Y, Ichinose M. Improvement of airflow limitation by fluticasone propionate/salmeterol in chronic obstructive pulmonary disease: what is the specific marker? Front Pharmacol. 2011;2:36. Scholar
  17. 17.
    Christenson SA, Steiling K, van den Berge M, Hijazi K, Hiemstra PS, Postma DS, Lenburg ME, Spira A, Woodruff PG. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191:758–66.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Respiratory Medicine and Infectious DiseaseGraduate School of Medicine, Yamaguchi UniversityUbeJapan

Personalised recommendations